{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-216716","form_type":"8-K","ticker":"AKTS","cik":"0002035832","company_name":"Aktis Oncology, Inc.","filed_at":"2026-05-11T20:04:15+00:00","discovered_at":"2026-05-11T20:05:00.609317+00:00","generated_at":"2026-05-11T22:54:19.626757+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Aktis Oncology Q1 2026 net loss $18.3M; cash $538.5M; Phase 1b trials advancing","bullets":["Net loss $18.3M vs $15.0M YoY; R&D expense $20.0M (+$4.1M) driven by clinical trial costs.","Cash, equivalents & marketable securities $538.5M (up from $226.8M Dec 2025); runway into 2029.","Initiated Phase 1b trial of AKY-2519 in mCRPC; second basket trial in H2 2026 for solid tumors.","AKY-1189 Phase 1b enrolling in multiple Nectin-4 tumors; preliminary data expected Q1 2027; FDA Fast Track for urothelial cancer.","Collaboration revenue $3.2M from Eli Lilly; appointed Glenn Gormley, MD, PhD to board."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-216716","json":"https://secwatch.observer/filing/0001193125-26-216716.json","markdown":"https://secwatch.observer/filing/0001193125-26-216716.md","text":"https://secwatch.observer/filing/0001193125-26-216716.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2035832/000119312526216716/0001193125-26-216716-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2035832/000119312526216716/ck0002035832-20260511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T22:54:19.626757+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}